NO20041180L - Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser - Google Patents

Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser

Info

Publication number: NO20041180L
Authority: NO; Norway
Prior art keywords: pyrrolopyrimidines; inhibition; agents; cysteine proteases; proteases
Prior art date: 2001-08-30

Application number

NO20041180A

Other languages

English (en)

Other versions

NO328890B1 (no

Inventor

Martin Missbach

Naoki Teno

Kenji Hayakawa

Genji Iwasaki

Claudia Betschart

Osamu Irie

Junichi Sakaki

Rene Lattmann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-30

Filing date

2004-03-19

Publication date

2004-03-19

2004-03-19 Application filed by Novartis Ag filed Critical Novartis Ag

2004-03-19 Publication of NO20041180L publication Critical patent/NO20041180L/no

2010-06-07 Publication of NO328890B1 publication Critical patent/NO328890B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20041180A 2001-08-30 2004-03-19 Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse NO328890B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0121033.5A GB0121033D0 (en)	2001-08-30	2001-08-30	Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en)	2001-08-30	2002-08-29	Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (2)

Publication Number	Publication Date
NO20041180L true NO20041180L (no)	2004-03-19
NO328890B1 NO328890B1 (no)	2010-06-07

Family

ID=9921234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041180A NO328890B1 (no)	2001-08-30	2004-03-19	Pyrrolopyrimidiner, anvendelse derav og farmasoytisk sammensetning omfattende en slik forbindelse

Country Status (29)

Country	Link
US (2)	US7452886B2 (no)
EP (1)	EP1423391B8 (no)
JP (1)	JP4629334B2 (no)
KR (1)	KR100695845B1 (no)
CN (1)	CN100372849C (no)
AR (1)	AR036374A1 (no)
AT (1)	ATE326469T1 (no)
AU (1)	AU2002333760B2 (no)
BR (1)	BR0212226A (no)
CA (1)	CA2458684C (no)
CY (1)	CY1105573T1 (no)
DE (1)	DE60211530T2 (no)
DK (1)	DK1423391T3 (no)
EC (1)	ECSP044998A (no)
ES (1)	ES2262888T3 (no)
GB (1)	GB0121033D0 (no)
HU (1)	HUP0401301A3 (no)
IL (3)	IL160367A0 (no)
MX (1)	MXPA04001935A (no)
MY (1)	MY157368A (no)
NO (1)	NO328890B1 (no)
NZ (1)	NZ531343A (no)
PE (1)	PE20030418A1 (no)
PL (1)	PL368280A1 (no)
PT (1)	PT1423391E (no)
RU (1)	RU2331644C2 (no)
TW (1)	TWI297690B (no)
WO (1)	WO2003020721A1 (no)
ZA (1)	ZA200401042B (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030144234A1 (en) *	2001-08-30	2003-07-31	Buxton Francis Paul	Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
GB0220187D0 (en) *	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
CN1708293A (zh)	2002-09-24	2005-12-14	诺瓦提斯公司	治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
AR043692A1 (es) *	2003-02-06	2005-08-10	Novartis Ag	2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) *	2003-02-28	2003-04-02	Novartis Ag	Organic compounds
US7498323B2 (en)	2003-04-18	2009-03-03	Ono Pharmaceuticals Co., Ltd.	Spiro-piperidine compounds and medicinal use thereof
AU2004233582B2 (en) *	2003-04-28	2008-05-15	Novartis Ag	Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1797883A3 (en) *	2003-04-28	2007-08-01	Novartis AG	Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
BRPI0409685A (pt) *	2003-04-30	2006-04-18	Fmc Corp	derivados cìclicos fenil-substituìdos
WO2005011703A1 (en) *	2003-08-04	2005-02-10	Akzo Nobel N.V.	2-cyano-1,3,5-triazine-4,6-diamine derivatives
CA2579609A1 (en)	2003-09-10	2005-03-17	Virochem Pharma Inc.	Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
JP5084269B2 (ja)	2004-02-18	2012-11-28	アストラゼネカアクチボラグ	テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
US20070197510A1 (en) *	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) *	2004-04-20	2007-07-01	Inke, S.A.	Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
AU2005243238B2 (en) *	2004-05-03	2011-11-10	Janssen Pharmaceutica N.V.	Novel indole derivatives as selective androgen receptor modulators (SARMS)
TW200614993A (en)	2004-06-11	2006-05-16	Akzo Nobel Nv	4-phenyl-pyrimidine-2-carbonitrile derivatives
US7951816B2 (en)	2004-08-27	2011-05-31	Ono Pharmaceutical Co., Ltd.	Compound containing basic group and use thereof
KR100651849B1 (ko) *	2005-02-01	2006-12-01	엘지전자 주식회사	세탁기
CA2617725C (en) *	2005-08-05	2012-04-03	Hybrigenics Sa	Novel cysteine protease inhibitors and their therapeutic applications
WO2007025991A2 (en)	2005-09-01	2007-03-08	Ares Trading S.A.	Treatment of optic neuritis
US7326715B2 (en)	2005-09-23	2008-02-05	N.V. Organon	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) *	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
PE20070530A1 (es) *	2005-10-26	2007-05-31	Smithkline Beecham Corp	Compuestos derivados de tiazoles sustituidos como agentes de apertura de canales de potasio activados por calcio de alta conductancia
PL1961744T3 (pl)	2005-11-18	2013-09-30	Ono Pharmaceutical Co	Związek zawierający grupę zasadową oraz jego zastosowanie
TW200804382A (en) *	2005-12-05	2008-01-16	Incyte Corp	Lactam compounds and methods of using the same
US7687515B2 (en)	2006-01-17	2010-03-30	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2042503B1 (en)	2006-05-16	2013-01-30	Ono Pharmaceutical Co., Ltd.	Compound having acidic group which may be protected, and use thereof
CN101511802A (zh)	2006-09-13	2009-08-19	阿斯利康(瑞典)有限公司	螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
TW200911803A (en) *	2007-07-16	2009-03-16	Organon Nv	6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en)	2007-07-16	2011-04-26	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP2011500673A (ja)	2007-10-19	2011-01-06	アストラゼネカ・アクチエボラーグ	代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
WO2009155475A1 (en)	2008-06-20	2009-12-23	Novartis Ag	Paediatric compositions for treating1 multiple sclerosis
TW201035094A (en)	2009-01-16	2010-10-01	Organon Nv	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en)	2009-01-16	2011-09-27	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
HRP20140754T2 (hr)	2009-06-29	2015-07-17	Incyte Corporation	Pirimidinoni kao inhibitori pi3k
US8759359B2 (en)	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011082273A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted pyrrolo-aminopyrimidine compounds
US9115126B2 (en)	2010-01-15	2015-08-25	Merck Sharp & Dohme B.V.	1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
WO2011130342A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
WO2012027495A1 (en)	2010-08-27	2012-03-01	University Of The Pacific	Piperazinylpyrimidine analogues as protein kinase inhibitors
ES2562274T3 (es)	2010-10-06	2016-03-03	Fundació Institut De Recerca Biomèdica (Irb Barcelona)	Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
WO2012087881A1 (en)	2010-12-20	2012-06-28	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
LT3196202T (lt)	2011-09-02	2019-07-10	Incyte Holdings Corporation	Heterociklilaminai, kaip pi3k slopikliai
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en)	2012-04-09	2013-10-16	Fundació Privada Institut de Recerca Biomèdica	Method for the prognosis and treatment of cancer metastasis
US9328118B2 (en) *	2012-04-17	2016-05-03	Astellas Pharma Inc.	Nitrogen-containing bicyclic aromatic heterocyclic compound
ES2705237T3 (es)	2012-06-06	2019-03-22	Fundacio Inst De Recerca Biomedica Irb Barcelona	Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
DK2906718T3 (da)	2012-10-12	2019-07-01	Inbiomotion Sl	Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
AU2014229505B2 (en)	2013-03-15	2020-02-27	Fundacio Institut De Recerca Biomedica (Irb Barcelona)	Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en)	2013-03-15	2016-02-04	Inbiomotion S.L.	Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
JP6550045B2 (ja)	2013-10-09	2019-07-24	フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）ＦｕｎｄａｃｉｏＩｎｓｔｉｔｕｔＤｅＲｅｃｅｒｃａＢｉｏｍｅｄｉｃａ（ＩｒｂＢａｒｃｅｌｏｎａ）	乳がんに由来する骨の転移がんの予後診断および処置のための方法
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP2017538412A (ja)	2014-12-11	2017-12-28	インバイオモーションエセ．エレ．	ヒトｃ−ｍａｆに対する結合メンバー
CN117736209A (zh)	2015-02-27	2024-03-22	因赛特控股公司	Pi3k抑制剂的盐及其制备方法
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
CN117230193A (zh)	2016-05-25	2023-12-15	生物运动有限公司	基于c-maf状态的乳腺癌治疗性治疗
EP3713581A1 (en)	2017-11-22	2020-09-30	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-maf
KR102054910B1 (ko) *	2017-12-19	2019-12-12	한림제약(주)	피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2019204354A1 (en)	2018-04-16	2019-10-24	C4 Therapeutics, Inc.	Spirocyclic compounds
EP3556760A1 (en) *	2018-04-19	2019-10-23	F. Hoffmann-La Roche AG	Spiro compounds
PE20211208A1 (es)	2018-06-01	2021-07-05	Incyte Corp	Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
WO2020201572A1 (en)	2019-04-05	2020-10-08	Université De Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022226166A1 (en) *	2021-04-22	2022-10-27	Protego Biopharma, Inc.	Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2023101048A1 (ko) *	2021-12-01	2023-06-08	에스티팜 주식회사	트리아졸로피리미디논 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE609808A (no) *	1960-11-02
CH627919A5 (de)	1977-04-14	1982-02-15	Ciba Geigy Ag	Herbizide mittel.
US5958930A (en) *	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
DK0682027T3 (da) *	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
US5683999A (en) *	1995-03-17	1997-11-04	The Dupont Merck Pharmaceutical Company	Cyclic urea HIV protease inhibitors
JP3290666B2 (ja) *	1995-06-07	2002-06-10	ファイザー・インコーポレーテッド	複素環式の縮合環ピリミジン誘導体
CA2283961A1 (en) *	1997-03-19	1998-09-24	Basf Aktiengesellschaft	Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
ATE347362T1 (de) *	1998-06-30	2006-12-15	Lilly Co Eli	Bicyclische spla 2-inhibitoren
JP2002526500A (ja) *	1998-09-18	2002-08-20	ビーエーエスエフアクチェンゲゼルシャフト	プロテインキナーゼ阻害剤としてのピロロピリミジン
CZ303875B6 (cs) *	1999-12-10	2013-06-05	Pfizer Products Inc.	Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
CA2402516A1 (en) *	2000-03-20	2001-09-27	Roopa Rai	Non-amidine containing protease inhibitors
AU2001241142B2 (en)	2000-04-28	2005-09-22	Tanabe Seiyaku Co., Ltd.	Cyclic compounds

2001
- 2001-08-30 GB GBGB0121033.5A patent/GB0121033D0/en not_active Ceased
2002
- 2002-08-27 MY MYPI20023181A patent/MY157368A/en unknown
- 2002-08-28 AR ARP020103229A patent/AR036374A1/es unknown
- 2002-08-28 TW TW091119570A patent/TWI297690B/zh not_active IP Right Cessation
- 2002-08-29 IL IL16036702A patent/IL160367A0/xx unknown
- 2002-08-29 BR BR0212226-0A patent/BR0212226A/pt not_active Application Discontinuation
- 2002-08-29 PT PT02797553T patent/PT1423391E/pt unknown
- 2002-08-29 DK DK02797553T patent/DK1423391T3/da active
- 2002-08-29 HU HU0401301A patent/HUP0401301A3/hu unknown
- 2002-08-29 PE PE2002000833A patent/PE20030418A1/es not_active Application Discontinuation
- 2002-08-29 US US10/487,760 patent/US7452886B2/en not_active Expired - Fee Related
- 2002-08-29 CA CA002458684A patent/CA2458684C/en not_active Expired - Fee Related
- 2002-08-29 NZ NZ531343A patent/NZ531343A/en not_active IP Right Cessation
- 2002-08-29 PL PL02368280A patent/PL368280A1/xx not_active Application Discontinuation
- 2002-08-29 AT AT02797553T patent/ATE326469T1/de active
- 2002-08-29 JP JP2003524991A patent/JP4629334B2/ja not_active Expired - Fee Related
- 2002-08-29 AU AU2002333760A patent/AU2002333760B2/en not_active Ceased
- 2002-08-29 ES ES02797553T patent/ES2262888T3/es not_active Expired - Lifetime
- 2002-08-29 RU RU2004109815/04A patent/RU2331644C2/ru not_active IP Right Cessation
- 2002-08-29 CN CNB028168402A patent/CN100372849C/zh not_active Expired - Fee Related
- 2002-08-29 MX MXPA04001935A patent/MXPA04001935A/es active IP Right Grant
- 2002-08-29 EP EP02797553A patent/EP1423391B8/en not_active Expired - Lifetime
- 2002-08-29 DE DE60211530T patent/DE60211530T2/de not_active Expired - Lifetime
- 2002-08-29 KR KR1020047003048A patent/KR100695845B1/ko not_active Expired - Fee Related
- 2002-08-29 WO PCT/EP2002/009663 patent/WO2003020721A1/en not_active Ceased
2004
- 2004-02-09 ZA ZA200401042A patent/ZA200401042B/en unknown
- 2004-02-12 IL IL160367A patent/IL160367A/en not_active IP Right Cessation
- 2004-03-01 EC EC2004004998A patent/ECSP044998A/es unknown
- 2004-03-19 NO NO20041180A patent/NO328890B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101095T patent/CY1105573T1/el unknown
2008
- 2008-09-25 US US12/237,896 patent/US20090054467A1/en not_active Abandoned
2009
- 2009-05-07 IL IL198643A patent/IL198643A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN100372849C (zh)	2008-03-05
US7452886B2 (en)	2008-11-18
CA2458684A1 (en)	2003-03-13
US20090054467A1 (en)	2009-02-26
TWI297690B (en)	2008-06-11
NZ531343A (en)	2006-01-27
PT1423391E (pt)	2006-09-29
CA2458684C (en)	2009-04-07
ZA200401042B (en)	2004-10-25
RU2331644C2 (ru)	2008-08-20
GB0121033D0 (en)	2001-10-24
ATE326469T1 (de)	2006-06-15
JP4629334B2 (ja)	2011-02-09
ECSP044998A (es)	2004-04-28
CN1549817A (zh)	2004-11-24
HK1072254A1 (zh)	2005-08-19
EP1423391A1 (en)	2004-06-02
BR0212226A (pt)	2004-08-17
CY1105573T1 (el)	2010-07-28
IL160367A (en)	2009-12-24
KR100695845B1 (ko)	2007-03-20
EP1423391B1 (en)	2006-05-17
US20050054851A1 (en)	2005-03-10
EP1423391B8 (en)	2007-12-12
DE60211530D1 (de)	2006-06-22
HUP0401301A2 (hu)	2004-10-28
AU2002333760B2 (en)	2007-01-04
IL160367A0 (en)	2004-07-25
HUP0401301A3 (en)	2008-03-28
RU2004109815A (ru)	2005-10-20
JP2005502683A (ja)	2005-01-27
MXPA04001935A (es)	2004-06-15
IL198643A (en)	2010-12-30
NO328890B1 (no)	2010-06-07
WO2003020721A1 (en)	2003-03-13
ES2262888T3 (es)	2006-12-01
KR20040029123A (ko)	2004-04-03
PL368280A1 (en)	2005-03-21
DE60211530T2 (de)	2006-12-21
MY157368A (en)	2016-06-15
DK1423391T3 (da)	2006-09-25
PE20030418A1 (es)	2003-06-12
AR036374A1 (es)	2004-09-01

Publication	Publication Date	Title
NO20041180L (no)	2004-03-19	Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser
NO20031065D0 (no)	2003-03-07	Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser
NO20033399D0 (no)	2003-07-30	Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033593L (no)	2003-08-13	Kinazoliner som MMP-13 inhibitorer
EP1272467A4 (en)	2003-05-07	Cathepsin cysteine protease inhibitors
NO20043158L (no)	2004-09-16	Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20033618L (no)	2003-10-15	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1666070T3 (da)	2008-01-14	Præparat til restenoseprofylakse
NO20035087D0 (no)	2003-11-14	Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20040084L (no)	2004-03-09	Peptid-baserte forbindelser
AU2002305926A1 (en)	2002-10-08	Cysteine protease inhibitors
NO20026283L (no)	2003-02-28	Inhibitorer av kobberholdige aminosydaser
NO20035728L (no)	2004-02-23	Pyrrolopyrimidiner som proteinkinaseinhibitorer
AU2002340031A1 (en)	2003-04-14	Compounds useful as reversible inhibitors of cysteine proteases
DK1442030T3 (da)	2006-12-27	Thiopen- og thiazolsulfonamider som antineoplastiske midler
DK1458447T3 (da)	2010-01-18	Kombination af cytokrom-p450-beroende proteasinhibitorer
FI20010558L (fi)	2002-09-20	Kappaleiden paikannus
DE60229764D1 (de)	2008-12-18	Entgratwerkzeug
NO20041968L (no)	2004-05-11	Anvendelse av cystationin
NO20033234L (no)	2003-09-22	Karotenoider som antihypertensjonsmidler
ATE330603T1 (de)	2006-07-15	Benzothiazolderivaten
NO20042057L (no)	2004-05-18	Fosfonsyreforbindelser som inhibitorer av serinproteaser
AU2002242500A1 (en)	2002-09-19	Cathepsin cysteine protease inhibitors
NO20030820D0 (no)	2003-02-21	Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
EP1450810A4 (en)	2005-11-30	XANTHINE INHIBITION

Legal Events

Date	Code	Title	Description
2012-03-26	MM1K	Lapsed by not paying the annual fees